The invention relates to novel compounds of the general formula (I),

##STR00001##

with Het-2 being an optionally substituted bicyclic heteroaryl of the formula

##STR00002##

pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Compositions, articles and methods for treating sleeplessness, anxiety, pain or inflammation include: (i) one or more pharmacologically active, non-psychoactive cannabinoids; (ii) one or more active agents; and an optional carrier or matrix. The optional carrier or matrix may comprise ingredients such as solvents, solid or dissolvable supports, fillers, flavorants, flavor or taste masking agents, and other adjuvants that provide the composition in a useful form factor configured for easy administration to a mammal of an appropriate pharmacological dosage of the active ingredients.

Compositions, articles and methods for treating sleeplessness, anxiety, pain or inflammation include: (i) one or more pharmacologically active, non-psychoactive cannabinoids; (ii) one or more active agents; and an optional carrier or matrix. The optional carrier or matrix may comprise ingredients such as solvents, solid or dissolvable supports, fillers, flavorants, flavor or taste masking agents, and other adjuvants that provide the composition in a useful form factor configured for easy administration to a mammal of an appropriate pharmacological dosage of the active ingredients.

The present disclosure describes products formulated to inhibit respiratory conditions and symptoms in animals, along with associated methods of providing such products to the animals. Feeding methods involve providing animals with a feed product that includes a direct-fed microbial composition, at least one phytogenic compound, and/or at least one vitamin. The direct-fed microbial composition includes one or more strains of Bacillus. The animals can include swine or cattle at risk of developing, or already afflicted with, a respiratory condition. Inhibition of respiratory stress can reduce mortality rates and medication administration relative to animals fed the same diet but lacking the feed product.

The present disclosure describes products formulated to inhibit respiratory conditions and symptoms in animals, along with associated methods of providing such products to the animals. Feeding methods involve providing animals with a feed product that includes a direct-fed microbial composition, at least one phytogenic compound, and/or at least one vitamin. The direct-fed microbial composition includes one or more strains of Bacillus. The animals can include swine or cattle at risk of developing, or already afflicted with, a respiratory condition. Inhibition of respiratory stress can reduce mortality rates and medication administration relative to animals fed the same diet but lacking the feed product.

The present disclosure describes products formulated to inhibit respiratory conditions and symptoms in animals, along with associated methods of providing such products to the animals. Feeding methods involve providing animals with a feed product that includes a direct-fed microbial composition, at least one phytogenic compound, and/or at least one vitamin. The direct-fed microbial composition includes one or more strains of Bacillus. The animals can include swine or cattle at risk of developing, or already afflicted with, a respiratory condition. Inhibition of respiratory stress can reduce mortality rates and medication administration relative to animals fed the same diet but lacking the feed product.

A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.

A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.

A method of enhancing absorption of a therapeutic agent sublingually in a person configured to treat chronic graft-versus-host disease (cGVHD) or aphthous stomatitis. The method includes administering a therapeutically effective amount of the therapeutic agent sublingually in a person and then inserting for a predetermined treatment period a device in an oral cavity of the person, wherein the device comprising an oral retention portion that is configured to be retained in the oral cavity from the predetermined treatment period and further configured to enhance absorption of the therapeutic agent sublingually.

A method of enhancing absorption of a therapeutic agent sublingually in a person configured to treat chronic graft-versus-host disease (cGVHD) or aphthous stomatitis. The method includes administering a therapeutically effective amount of the therapeutic agent sublingually in a person and then inserting for a predetermined treatment period a device in an oral cavity of the person, wherein the device comprising an oral retention portion that is configured to be retained in the oral cavity from the predetermined treatment period and further configured to enhance absorption of the therapeutic agent sublingually.